Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05577624 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05577624 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 14 participants.
The verdict
NCT05577624, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
Interventions
- DRUG Rifampin
- DRUG AMG 510
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-11-05 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05577624
The ClinicalTrials.gov registry entry for NCT05577624 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT05577624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05577624 about?
NCT05577624 is a clinical study titled "A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants". The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of AMG 510 alone and in combination with rifampin in healthy participants.
What is the current status of trial NCT05577624?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-11-05. Estimated completion is 2019-12-01.
What interventions are being tested in trial NCT05577624?
The interventions under investigation include: Rifampin (DRUG), AMG 510 (DRUG).
Who is sponsoring clinical trial NCT05577624?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.